Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Bewersdorf, Jan Philipp
[Clear All Filters]
2018
Liu Y
,
Bewersdorf JPhilipp
,
Stahl M
,
Zeidan AM
.
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
. Blood Rev. 2018.
PubMed
Google Scholar
2019
Bewersdorf JPhilipp
,
Stahl M
,
Zeidan AM
.
One plus one does not always equal two, especially with regard to hypomethylating agents: The question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic
. Expert Rev Hematol. 2019.
PubMed
Google Scholar
2021
Bewersdorf JPhilipp
,
Allen C
,
Mirza A-S
,
Grimshaw AA
,
Giri S
,
Podoltsev NA
,
Gowda L
,
Cho C
,
Tallman MS
,
Zeidan AM
, et al.
Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant - a systematic review and meta-analysis.
Transplant Cell Ther. 2021.
PubMed
Google Scholar
2023
Stahl M
,
Bewersdorf JPhilipp
,
Xie Z
,
Porta MGiovanni D
,
Komrokji R
,
Xu ML
,
Abdel-Wahab O
,
Taylor J
,
Steensma DP
,
Starczynowski DT
, et al.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Blood Rev. 2023:101128.
PubMed
Google Scholar
Bewersdorf JPhilipp
,
Xie Z
,
Bejar R
,
Borate U
,
Boultwood J
,
Brunner AM
,
Buckstein R
,
Carraway HE
,
Churpek JE
,
Daver NG
, et al.
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Blood Rev. 2023:101072.
PubMed
Google Scholar
2024
Kewan T
,
Stahl M
,
Bewersdorf JPhilipp
,
Zeidan AM
.
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Curr Hematol Malig Rep. 2024.
PubMed
Google Scholar